Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | MET | P08581 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | PIM1 | P11309 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CDC7 | O00311 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.46 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2263427 | 0.76 | HTT (0.64) | KMT2AHTTSMN1; SMN2TDP1MET | |
| SCHEMBL12368772 | 0.75 | MET (0.55) | KMT2AHTTSMN1; SMN2TDP1MET | |
| SCHEMBL1187561 | 0.71 | SMN1; SMN2 (0.64) | KMT2AHTTSMN1; SMN2TDP1MET | |
| SCHEMBL5619568 | 0.70 | HTT (0.55) | KMT2AHTTSMN1; SMN2TDP1POLB | |
| SCHEMBL8792583 | 0.68 | HTT (0.51) | KMT2AHTTSMN1; SMN2TDP1POLB | |
| SCHEMBL8794028 | 0.67 | KMT2A (0.54) | KMT2AHTTSMN1; SMN2POLBRXFP1 | |
| SCHEMBL11750772 | 0.67 | PIM1 (0.75) | KMT2AHTTSMN1; SMN2TDP1PIM1 | |
| SCHEMBL11846002 | 0.66 | HTT (0.49) | HTTSMN1; SMN2TDP1METRXFP1 | |
| SCHEMBL4783215 | 0.66 | PIM1 (0.78) | KMT2AHTTSMN1; SMN2TDP1PIM1 | |
| SCHEMBL12049154 | 0.66 | MET (0.67) | MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7173033-B2 | Nitrogen-containing heterocyclic compound | ASTELLAS PHARMA INC. (JP) | 2007-02-06 | — | — | US | disclosed |
| US-20060173009-A1 | Agent inducing increase in bone mass | ASTELLAS PHARMA INC. (JP) | 2006-08-03 | — | — | US | disclosed |
| EP-1640010-A1 | AGENT INDUCING INCREASE IN BONE MASS | Astellas Pharma Inc. (JP) | 2006-03-29 | — | — | EP | disclosed |
| US-20050261297-A1 | Nitrogen-containing heterocyclic compound | YAMANOUCHI PHARMACEUTICAL CO., LTD | 2005-11-24 | — | — | US | disclosed |
| US-20050096322-A1 | Nitrogen-containing heterocyclic compound | ASTELLAS PHARMA INC. (JP) | 2005-05-05 | — | — | US | disclosed |
| EP-1481977-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096322-A1 | Nitrogen-containing heterocyclic compound | BMP2, BMP1, BMP4 | KMT2A 3852/4885HTT 3135/4885SMN1; SMN2 1838/4885 |
| US-20050261297-A1 | Nitrogen-containing heterocyclic compound | BMP2, BMP1, BMP4 | KMT2A 3852/4885HTT 3135/4885SMN1; SMN2 1838/4885 |
| US-20060173009-A1 | Agent inducing increase in bone mass | SOST, CALCB, BMP4 | KMT2A 4477/4885HTT 4745/4885SMN1; SMN2 3403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.